ResMed Inc. Reports Strong Third‑Quarter Fiscal 2026 Results

Fiscal Performance

ResMed Inc. announced its third‑quarter fiscal 2026 results, reporting revenue that increased in the high‑teens percentage range and earnings per share (EPS) that surpassed market expectations. The company attributes this performance to a combination of higher product volumes, a broadened product portfolio, and significant gains in manufacturing efficiency.

  • Revenue: $1.32 billion, up 18 % YoY.
  • Gross Margin: 60.2 %, reflecting improved operational leverage.
  • Net Income: $260 million, yielding an EPS of $1.60 versus the consensus estimate of $1.48.

The company’s guidance for the remaining fiscal year remains unchanged, maintaining a focus on sustained growth in both North American and international markets.

Product Expansion

ResMed introduced a new mask model—designated the ResMed‑AirSense‑X—in the United States during the reporting quarter. The device incorporates a novel soft‑tissue‑contact interface that has demonstrated reduced skin irritation in a multicenter clinical trial involving 1,200 patients with obstructive sleep apnea (OSA). Safety data from the trial met all FDA criteria for Class I medical devices, and the product received 510(k) clearance in September 2025. The AirSense‑X is currently CE‑marked and is expected to expand ResMed’s market share in the competitive CPAP mask segment.

Manufacturing and Distribution

ResMed highlighted a 12 % reduction in per‑unit manufacturing costs attributable to process automation and lean‑production initiatives implemented across its U.S. facilities. In addition, the company announced plans to open a new distribution center in Evansville, Indiana, which will serve the Midwest and southern U.S. markets. The facility is projected to increase logistical efficiency by 20 % and support the company’s growing e‑commerce channel.

Financial Policy

A quarterly dividend of $0.60 per share was declared, bringing the annual dividend to $2.40. The dividend yield stands at 2.8 % based on the current share price. Investors welcomed the dividend payout, though the market adjusted for the CFO transition.

Leadership Transition

Chief Financial Officer Brett Sandercock announced his retirement at the end of the quarter. Aaron Bloomer, formerly ResMed’s Vice President of Finance and Strategy, will assume the CFO role on July 1, 2026. Bloomer’s appointment is expected to preserve continuity in the company’s financial stewardship while reinforcing its strategic focus on capital allocation and shareholder returns.

Market Reaction

The company’s share price fell modestly by 1.3 % in after‑hours trading, a movement attributed to the CFO change and the broader volatility observed in Australian‑listed technology stocks. Despite this, institutional holdings remained largely unchanged, and the market’s long‑term view of ResMed’s growth trajectory appears stable.

Strategic Outlook

ResMed reaffirms its commitment to global access to respiratory care and to expanding its digital health ecosystem. The company is currently pursuing FDA clearance for a remote monitoring platform that integrates CPAP data with electronic health records, which could streamline care coordination and improve treatment adherence. Regulatory pathways for this platform involve a pre‑market notification (510(k)) submission, with anticipated review timelines of 90–120 days.

In summary, ResMed’s third‑quarter fiscal 2026 results demonstrate robust financial performance, effective product innovation, and disciplined manufacturing practices. The company’s strategic initiatives—particularly the introduction of the AirSense‑X, the new Indiana distribution center, and the expansion of digital health solutions—position it well for continued growth in a competitive marketplace while maintaining a strong emphasis on safety, efficacy, and regulatory compliance.